ArticleMedical oncology (Northwood, London, England)2026
Effect of siRNA-mediated knockdown of the PD-L1 (CD274) gene on DUSP gene family expression and potential clinical implications in gastric cancer.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the molecular interaction between PD-L1 (CD274) and members of the dual-specificity phosphatase (DUSP) gene family (DUSP1, DUSP2, DUSP4, DUSP6, and DUSP10) in gastric adenocarcinoma (GC) using integrated bioinformatic and experimental approaches. Bioinformatic analyses based on UALCAN, GEPIA, TIMER 2.0, and STRING databases revealed significant dysregulation of PD-L1 (CD274), DUSP2, DUSP4, DUSP6, and DUSP10 in tumor tissues, while DUSP1 was downregulated. Gene expression patterns were associated with tumor stage and patient prognosis. Promoter methylation analyses suggested epigenetic regulation of PD-L1 (CD274), DUSP1, and DUSP2, and copy number variation analysis indicated that gene amplifications were associated with altered immune cell infiltration, particularly dendritic cells and T lymphocytes. Gene expression was further evaluated in gastric tumor and adjacent non-tumor tissues using the GEO dataset GSE27342. Functional validation using siRNA-mediated PD-L1 (CD274) knockdown in AGS gastric cancer cells (GC) resulted in reduced cell viability, induction of apoptosis, upregulation of DUSP4, and downregulation of DUSP2. qPCR analysis of patient-derived tissue samples demonstrated significant alteration of DUSP6 expression, while peripheral blood analysis revealed significant suppression of DUSP2 in GC patients compared to controls. Logistic regression and ROC analyses identified DUSP6 (tissue level) and DUSP2 (blood level) as the most statistically relevant markers among the evaluated genes. Collectively, these findings suggest that PD-L1 (CD274) influences tumor cell survival not only through immune checkpoint signaling but also through modulation of MAPK-associated phosphatases. The coordinated dysregulation of PD-L1 (CD274), DUSP2, and DUSP6 supports the existence of a functional PD-L1/DUSP signaling axis in gastric cancer pathogenesis and highlights its potential relevance for future diagnostic and therapeutic investigations.
Indexed as
Identifiers
42848101What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.